G vs. EXPO, FCN, ICFI, HURN, BAH, SPXC, FCFS, FOUR, KVYO, and MARA
Should you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Exponent (EXPO), FTI Consulting (FCN), ICF International (ICFI), Huron Consulting Group (HURN), Booz Allen Hamilton (BAH), SPX Technologies (SPXC), FirstCash (FCFS), Shift4 Payments (FOUR), Klaviyo (KVYO), and Marathon Digital (MARA). These companies are all part of the "business services" sector.
Exponent (NASDAQ:EXPO) and Genpact (NYSE:G) are both mid-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Exponent presently has a consensus target price of $99.50, suggesting a potential upside of 6.76%. Genpact has a consensus target price of $39.78, suggesting a potential upside of 28.07%. Given Exponent's higher probable upside, analysts clearly believe Genpact is more favorable than Exponent.
Genpact has higher revenue and earnings than Exponent. Genpact is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.
Exponent has a net margin of 18.72% compared to Exponent's net margin of 14.10%. Genpact's return on equity of 28.13% beat Exponent's return on equity.
Exponent has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Genpact has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Genpact received 182 more outperform votes than Exponent when rated by MarketBeat users. Likewise, 68.44% of users gave Genpact an outperform vote while only 63.09% of users gave Exponent an outperform vote.
Exponent pays an annual dividend of $1.12 per share and has a dividend yield of 1.2%. Genpact pays an annual dividend of $0.61 per share and has a dividend yield of 2.0%. Exponent pays out 56.6% of its earnings in the form of a dividend. Genpact pays out 17.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Exponent has increased its dividend for 6 consecutive years and Genpact has increased its dividend for 7 consecutive years. Genpact is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
92.4% of Exponent shares are held by institutional investors. Comparatively, 96.0% of Genpact shares are held by institutional investors. 2.2% of Exponent shares are held by insiders. Comparatively, 2.8% of Genpact shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Exponent had 11 more articles in the media than Genpact. MarketBeat recorded 22 mentions for Exponent and 11 mentions for Genpact. Exponent's average media sentiment score of 0.41 beat Genpact's score of 0.13 indicating that Genpact is being referred to more favorably in the news media.
Summary
Genpact beats Exponent on 13 of the 20 factors compared between the two stocks.
Get Genpact News Delivered to You Automatically
Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
